Larimar Therapeutics Q3 2026 Results: Net Loss of $31.1M, Loss Narrows
Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.
- Key figure
- Net loss $31.1M